SLQT — SelectQuote, Inc.

SelectQuote (SLQT) Q2 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Revenue: $537 million, up 12% year-over-year.
• Senior Revenue: $262 million, a 2% increase driven by higher approved policy volumes.
• Healthcare Services Revenue: $231 million, a 26% increase year-over-year.
• EBITDA Margins: Near-record levels at 39% for the senior segment, resulting in adjusted EBITDA of $102 million.
• Operating Cash Flow: Expected to be between $25 million and $35 million for fiscal 2026, a significant improvement from the previous year.

2. Strategic Updates and Business Highlights

• Medicare Advantage (MA) Season: Successful execution led to a 4% growth in policy volume, with strong agent productivity and marketing efficiency.
• SelectRx Growth: The healthcare services segment continues to expand, with a focus on improving medication adherence and reducing hospitalizations through innovative delivery services.
• New PBM Agreement: A multiyear agreement with a key pharmacy benefit manager enhances visibility into drug reimbursement pricing, aiming to improve profitability.
• Credit Facility: A new $415 million credit facility provides greater capital flexibility and extends debt maturities to 2031.

3. Forward Guidance and Outlook

• Revised Fiscal 2026 Guidance: Consolidated revenue is now expected to be between $1.61 billion and $1.71 billion, with adjusted EBITDA projected between $90 million and $100 million, reflecting a $40 million aggregate impact from a national carrier's marketing budget cuts and PBM reimbursement changes.
• Long-term Outlook: Despite the short-term challenges, management remains confident in achieving 20% plus EBITDA margins for the senior division and an annualized adjusted EBITDA exit rate of $40 million to $50 million for healthcare services.

4. Bad News, Challenges, or Points of Concern

• Guidance Reduction: The need to lower fiscal 2026 guidance due to a $20 million impact from a national carrier's marketing budget cuts and another $20 million from PBM reimbursement changes.
• Market Dynamics: Increased competition and shifting policy features in the Medicare Advantage market pose ongoing challenges.
• Advanced Rate Notice: Disappointment with the CMS's preliminary advanced rate notice for 2027, which may not reflect rising utilization and care costs.

5. Notable Q&A Insights

• PBM Deal Clarification: Management emphasized that the new PBM agreement provides stability and predictability, mitigating the $20 million hit as a one-time issue.
• Carrier Marketing Cuts: The decision by a major carrier to cut marketing budgets was described as a broader industry trend, but management expressed confidence in navigating through it.
• Negotiation Leverage: The scale of SelectRx has improved its negotiating position with pharmacy partners, allowing for deeper partnerships and better terms.
• Operational Flexibility: The new credit facility allows SelectQuote to strategically deploy capital across its diversified business model, focusing on profitability and cash flow.

Overall, while SelectQuote experienced some unexpected headwinds in Q2 2026, the company demonstrated strong operational execution and remains optimistic about its long-term growth potential.